Calreticulin binding and other biological activities of survival peptide Y-P30 including effects of systemic treatment of rats.
Neuron survival-promoting peptide Y-P30, purified from oxidatively stressed neural cell lines, inhibits the appearance of microglia and rescues neurons 1 week after direct application to lesions of the rat cerebral cortex (7). Y-P30 affinity matrices treated with solubilized membranes from a variety of cell lines including human neuroblastoma SY5Y, mouse hippocampal cells HN 33.1, and human promonocytes HL-60, as well as with cerebral cortex tissue from both humans and rats, showed highly specific binding to calreticulin, a ubiquitous calcium binding protein that may be critical for integrin function. Treatment of cultures with 0.1 nM Y-P30 stabilized all these cell types whether differentiated or not, while 1 microM peptide also inhibited the morphological differentiation of the HL-60 cells into macrophages. Western analysis of the medium of SY5Y cell cultures suggested Y-P30-stimulated release of calreticulin, a result consistent with its other biological activities. Likewise, single dose systemic application of Y-P30 in unoperated rats and in rats with cerebral cortex lesions produced significant reductions in cerebral cortex membrane-associated calreticulin. Both direct and intravenous treatment with peptide also reduced cortical neuron atrophy 4 days after these lesions but only direct application consistently inhibited the appearance of ED-1(+) monocyte derivatives. We suggest that in vitro and in vivo mechanisms of Y-P30 effects are similar and involve the targeting of calreticulin. The results also suggest that some of these activities are apparent in the cerebral cortex after systemic application of this peptide.
Cunningham
T J
TJ
Department of Neurobiology and Anatomy, MCP-Hahnemann University, 3200 Henry Avenue, Philadelphia, Pennsylvania 19129, USA.
Jing
H
H
Wang
Y
Y
Hodge
L
L
D000818:Animals; D002135:Calcium-Binding Proteins / Q000187:drug effects / Q000378:metabolism*; D037282:Calreticulin; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002540:Cerebral Cortex / Q000187:drug effects / Q000293:injuries / Q000378:metabolism*; D018922:HL-60 Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D051379:Mice; D009447:Neuroblastoma / Q000378:metabolism; D009479:Neuropeptides / Q000138:chemical synthesis / Q000494:pharmacology*; D051381:Rats; D020318:Rats, Long-Evans; D012261:Ribonucleoproteins / Q000187:drug effects / Q000378:metabolism*
D002135:Calcium-Binding Proteins; D037282:Calreticulin; D009479:Neuropeptides; D012261:Ribonucleoproteins